What Disease Is Melatonin Linked To?

You've heard melatonin is "safe and natural." But recent research reveals a more nuanced story. While melatonin supplements help millions with sleep, emerging evidence shows links to cardiovascular disease, cognitive decline, and metabolic dysfunction—yet paradoxically, it also shows protective properties against the same conditions when your body produces it naturally.

This contradiction isn't a research error. It reflects a critical distinction: the diseases melatonin is "linked to" depend on context. Low melatonin production predicts disease risk. Long-term supplementation in certain populations increases disease risk. Yet in others, melatonin supplementation offers disease prevention and therapeutic benefits.

Understanding these disease associations isn't about creating fear—it's about using melatonin safely and knowing when medical supervision matters.

Table of Contents

1. Cardiovascular Disease: The Heart Failure Connection
2. Neurodegenerative Diseases: Dementia, Alzheimer's & Parkinson's
3. Metabolic Diseases: Diabetes, Obesity & Metabolic Syndrome
4. Cancer Risk & Circadian Disruption
5. Natural Melatonin Deficiency vs. Supplementation
6. Dose, Duration & Individual Risk Factors
7. What Clinical Evidence Actually Shows

1. Cardiovascular Disease: The Heart Failure Connection

In November 2025, the American Heart Association presented research that shook the "melatonin is safe" narrative. Using electronic health records from 130,828 adults with insomnia, researchers found that long-term melatonin use (12+ months) was associated with an 89% increased risk of heart failure diagnosis over five years, compared to insomnia patients who never used melatonin.

The findings were striking: 4.6% of melatonin users developed heart failure versus 2.7% of non-users—an absolute risk difference of 1.9%. More concerning, melatonin users experienced a 3.4-fold increase in heart failure-related hospitalizations (19% vs. 6.6%) and a 2.1-fold increase in all-cause mortality. These associations remained consistent even after researchers adjusted for 40+ baseline variables including age, sex, prior heart disease, blood pressure, and BMI.

What's critical to understand: This study examined association, not direct causation. The research team hypothesized that melatonin may be masking underlying cardiac symptoms rather than directly causing heart disease. Insomnia itself is a known risk factor for cardiovascular disease, increasing blood pressure, stress hormones, and systemic inflammation. A supplement that improves sleep quality without addressing the underlying cardiac risk could delay diagnosis of developing heart failure until the condition becomes severe—a form of medical harm even if melatonin itself doesn't "cause" the disease.

2. Neurodegenerative Diseases: Dementia, Alzheimer's & Parkinson's

The disease association for neurodegenerative conditions tells an opposite story. Reduced melatonin levels are consistently documented across the Alzheimer's disease continuum, with deficiencies appearing before diagnosis. Researchers have proposed melatonin as a potential biomarker for early neurodegeneration, and evidence suggests low melatonin may contribute to disease progression rather than result from it.

In both Alzheimer's disease and Parkinson's disease, researchers identified melatonin deficiency at the pineal gland level—a consequence of age-related calcification that typically begins in the third decade of life. Sleep disturbances often precede cognitive decline by years, and melatonin's known antioxidant and anti-inflammatory properties suggest mechanisms by which supplementation could theoretically slow neurodegeneration.

Clinical evidence is modest but consistent. A 2021 meta-analysis of randomized controlled trials in Alzheimer's disease found that melatonin supplementation (0.15–6 mg before bed) improved cognitive function as measured by the Mini-Mental State Examination, with a mean improvement of 1.82 points (p<0.0001). Melatonin also improved sleep quality and reduced "sundowning"—the agitation and confusion that emerges in late afternoon in dementia patients. A 2026 meta-analysis in chronic kidney disease patients found melatonin use associated with improved lipid profiles, reduced oxidative stress, and improved sleep—all correlated with lower dementia risk.

The current research consensus: melatonin may be most effective as a prophylactic agent early in the disease process, slowing neurodegeneration before irreversible cognitive loss occurs. Once significant neurodegeneration has occurred, melatonin appears unable to reverse damage, only potentially slow progression. This timing distinction is crucial for clinical application—melatonin may prevent disease but cannot cure it.

3. Metabolic Diseases: Diabetes, Obesity & Metabolic Syndrome

Metabolic syndrome—the clustering of obesity, insulin resistance, hypertension, and dyslipidemia—affects more than 25% of the population in developed countries and increases cardiovascular disease and diabetes risk. Research consistently shows that adults with metabolic syndrome have lower circulating melatonin levels than healthy controls, and this deficiency appears causally linked to metabolic dysfunction.

In animal models, the evidence is compelling. Melatonin supplementation (at doses equivalent to 15 micrograms per milliliter in rodent studies) reversed fructose-induced metabolic syndrome, reducing systolic blood pressure, total cholesterol, LDL cholesterol, triglycerides, and body weight. These effects reflect melatonin's roles in mitochondrial function, antioxidant defense, and immune regulation—all dysregulated in metabolic disease.

In humans, the picture is murkier. A 2024 study of 81 elderly patients treated with high-dose melatonin (40–200 mg daily, mean 72.7 mg) for more than 4 years found significant improvement in arterial hypertension, ischemic heart disease, and diabetes mellitus compared to untreated controls. However, the dose range (10–200 mg daily) far exceeds typical supplementation (1–10 mg), and the study was retrospective without randomization—limiting causal inference.

Three prospective cohorts followed middle-aged and older adults (Nurses' Health Study, Health Professionals Follow-up Study, Nurses' Health Study II) for up to 23 years. Melatonin supplement use was not associated with increased type 2 diabetes or cardiovascular disease risk in pooled analysis. Notably, in subgroup analyses, melatonin appeared to attenuate the cardiovascular risk associated with long-term shift work (p=0.013)—suggesting potential benefit in circadian-disrupted populations specifically.

4. Cancer Risk & Circadian Disruption

Melatonin's role in cancer risk remains one of the most researched and least conclusive areas. The association is indirect: circadian disruption suppresses melatonin production and is classified as a probable carcinogen by the International Agency for Research on Cancer. Night shift workers, who experience chronic circadian desynchrony and melatonin suppression, show increased breast cancer risk and other malignancies.

In animal models and cell culture studies, melatonin demonstrates antitumor activity through multiple mechanisms: antioxidant effects reducing DNA damage, immune modulation enhancing tumor surveillance, and direct anti-proliferative effects on cancer cells. However, translating these preclinical findings to human supplementation remains challenging. Most clinical evidence comes from observational studies or small trials, not large-scale randomized controlled trials.

The practical distinction: low melatonin production (from shift work, chronic light exposure at night, or aging) is associated with increased cancer risk. Whether supplementation prevents cancer in humans remains unknown. Cancer researchers emphasize that maintaining natural circadian rhythms—through light exposure management, consistent sleep schedules, and appropriate darkness at night—is a more evidence-based cancer prevention strategy than melatonin supplementation alone.

5. Natural Melatonin Deficiency vs. Supplementation: The Critical Distinction

The diseases melatonin is "linked to" depend almost entirely on context: whether you're examining disease in the presence of melatonin deficiency or disease in the presence of melatonin supplementation. These are different phenomena.

Melatonin Deficiency → Disease Association: Low endogenous melatonin production is linked to cardiovascular disease, neurodegenerative disease, metabolic syndrome, and cancer. This association likely reflects both direct pathological effects of melatonin loss and the underlying circadian dysregulation that causes it. Age-related decline in melatonin production accelerates after age 50, correlating with increased disease incidence in aging populations.

Melatonin Supplementation → Mixed Outcomes: Taking exogenous melatonin supplements produces different outcomes depending on population, dose, duration, and baseline health status. In healthy adults taking 1–5 mg short-term for jet lag or mild sleep issues, side effects are rare and mild (headaches, dizziness, gastrointestinal symptoms most common). In adults with chronic insomnia taking melatonin long-term (12+ months), cardiovascular risk increases. In older adults with cognitive impairment, modest cognitive benefits with acceptable safety. In shift workers, protective cardiovascular effects against shift work-associated disease.

This distinction matters clinically. Low melatonin is a risk factor. Melatonin supplementation is an intervention with context-dependent outcomes. The goal is restoring healthy melatonin physiology—which may involve supplementation for some populations but involves circadian rhythm restoration, light management, and lifestyle optimization for others.

6. Dose, Duration & Individual Risk Factors: Why Context Matters

The recent heart failure research used data from patients who filled prescriptions (either 1 prescription or 2+ prescriptions at least 90 days apart), reflecting "melatonin use" but not distinguishing between occasional use, nightly use, or dosing patterns. This matters because disease risk likely follows a dose-response and duration-response curve.

Natural melatonin production peaks in the evening at approximately 100–200 picograms per milliliter and returns to near-zero during daytime. A typical 5 mg supplement can produce serum levels 2–3 times physiological peaks. High-dose melatonin (20–50 mg), promoted by some researchers for neuroprotection or cancer prevention, produces supraphysiological levels for 6–12+ hours. Animal studies showing neuroprotective effects typically use doses of 100+ mg/kg—equivalent to 7,000–10,000 mg in humans—far beyond any recommended supplement protocol.

Long-term supplementation effects are poorly understood in humans. The heart failure study examined 5-year outcomes in a population with chronic insomnia. Results may not generalize to younger, healthier populations or short-term use for jet lag. Shift workers, who experience circadian disruption similar to insomnia patients, showed cardiovascular benefit from melatonin in subgroup analysis—suggesting disease risk depends on the underlying condition melatonin is treating.

Individual risk factors that likely modulate melatonin's effects include age (older adults may have different pharmacokinetics), baseline cardiovascular health, medications, genetic factors affecting melatonin receptor sensitivity, and comorbid conditions like sleep apnea. A safe dose for a 30-year-old shift worker may carry different risk profile for a 70-year-old with hypertension and prior myocardial infarction.

7. What Clinical Evidence Actually Shows: The Nuanced Truth

Media headlines about melatonin often polarize: either "safe miracle supplement" or "dangerous risk factor." The clinical evidence reveals neither extreme. Instead, it shows a medication-like substance with genuine therapeutic effects in specific populations and real safety concerns in others.

The evidence hierarchy matters. The strongest evidence comes from large prospective cohort studies (like the Nurses' Health Study with 158,000+ participants over 23 years showing no increased cardiovascular disease or diabetes risk) and well-designed randomized controlled trials. Medium-strength evidence comes from case-control studies and smaller trials. Weakest evidence comes from animal studies or isolated cell culture findings, which often fail to translate to humans.

On heart failure: One large observational study (130,828 participants, TriNetX database, 2025) found 89% increased risk with long-term insomnia-associated melatonin use. This is remarkable evidence warranting medical attention, but it is not randomized and cannot prove causation. Confounding factors—unmeasured cardiac conditions, medication interactions, or behavioral factors—could explain the association. Future randomized trials may clarify whether risk is real or explained by indication (sicker patients taking more melatonin).

On dementia: Multiple meta-analyses and small randomized trials show modest improvements in sleep and cognition with melatonin 1–6 mg in people with Alzheimer's disease. These improvements are real but modest (1–2 point differences on cognitive scales). Evidence strongest for sleep improvement, weaker for cognitive change. Animal studies suggest higher doses (not typically supplemented) produce stronger neuroprotection, suggesting human trials with higher doses or earlier disease stages might yield different results.

On metabolic disease: Prospective cohorts show no increased diabetes or cardiovascular risk with melatonin supplementation in general populations. Animal studies and small human trials show metabolic benefit, particularly with higher doses or in circadian-disrupted populations. The evidence suggests potential benefit but isn't robust enough for clinical recommendations yet.

BioAbsorb Liposomal Melatonin—Optimized Delivery for Better Absorption

Understanding disease associations raises a practical question: if you choose to supplement with melatonin, how do you maximize benefits while minimizing risks? Delivery matters more than most people realize.

Standard melatonin supplements face absorption challenges. Melatonin is lipophilic (fat-soluble) but is formulated in aqueous solutions that inefficiently cross the intestinal barrier. Bioavailability varies dramatically between products—some commercial supplements deliver only 10–20% of labeled melatonin to circulation, while others approach 80%. This inconsistency means identical doses produce vastly different serum levels, affecting both efficacy and safety profile.

BioAbsorb Liposomal Melatonin addresses this absorption problem through liposomal encapsulation—wrapping melatonin in phospholipid spheres that mimic cellular membranes. This structure increases bioavailability, stabilizes the hormone against degradation, and extends peak serum levels closer to physiological durations. Research on melatonin bioavailability consistently shows that liposomal and other advanced delivery systems produce 2–3 times higher absorption than standard preparations.

For populations considering melatonin use—older adults addressing cognitive concerns, shift workers managing circadian disruption, or insomnia patients—optimized delivery means lower effective doses achieve target effects. Lower doses reduce circulating melatonin levels closer to physiological ranges, potentially minimizing long-term disease risk from supraphysiological supplementation. This is particularly important for adults considering long-term use, where dose and duration both predict cardiovascular risk in recent evidence.

BioAbsorb formulations also use dosing protocols aligned with chronobiological science: melatonin timing matched to circadian phase and duration matched to natural melatonin physiology (evening peak, rapid daytime clearance). This protocol-based approach differs from constant daily melatonin, which may produce chronic supraphysiological levels disrupting natural circadian regulation.

Frequently Asked Questions

Does melatonin cause heart disease?

Recent research shows association, not causation. Long-term melatonin use in insomnia patients is associated with increased heart failure risk, but the mechanism remains unclear. Melatonin may mask developing cardiac symptoms, or the association may reflect residual confounding despite matching on 40+ variables. Importantly, prospective cohort studies in general adult populations show no increased cardiovascular disease with melatonin supplementation. Risk appears specific to chronic insomnia populations taking melatonin long-term. Consult your physician before long-term melatonin use if you have cardiac risk factors.

Can melatonin prevent Alzheimer's disease?

Animal evidence is promising—melatonin shows antioxidant, anti-inflammatory, and amyloid-clearing properties in neurodegenerative disease models. Human evidence is weaker. Studies in existing Alzheimer's patients show modest improvements in sleep and modest improvements in cognitive scores. Most research suggests melatonin works best as a preventive agent (in people at risk for dementia) rather than a treatment for existing disease. Long-term randomized trials in cognitively normal older adults are needed to determine if melatonin prevents cognitive decline.

Is melatonin safe for long-term use?

Short-term safety is excellent—adverse events are mild and rare (headaches, dizziness, gastrointestinal symptoms). Long-term safety (12+ months) is less established. The heart failure association raises concerns about continuous daily supplementation, particularly in high-risk populations. Dose and delivery method matter. Lower doses with optimized absorption (like liposomal formulations) achieve effects with less systemic melatonin exposure. Periodic use (for jet lag, shift work adaptation) appears safer than continuous daily supplementation. Discuss long-term use plans with your healthcare provider if you have cardiovascular risk factors or comorbid conditions.

Can melatonin cause cancer?

No direct evidence links melatonin supplementation to cancer. In fact, melatonin shows anticancer properties in laboratory studies. However, low melatonin production (from circadian disruption, night shift work, or aging) is associated with increased cancer risk. The evidence suggests the issue is insufficient melatonin, not too much. If considering melatonin supplementation for cancer prevention, talk with your oncologist—most cancer prevention evidence supports circadian rhythm optimization and light exposure management over supplementation alone.

What dose of melatonin is safe for long-term use?

Evidence suggests 1–5 mg taken 30–60 minutes before bed is effective for sleep without producing highly supraphysiological levels. Higher doses (10–20 mg) don't show proportionally better sleep results but do produce higher circulating levels. For long-term use, lower doses with optimized bioavailability (liposomal or other advanced delivery) may be preferable to higher standard supplements, as they achieve effects with less systemic melatonin exposure. Dose timing (evening only, not continuous) closer matches natural physiology. Individual optimization requires working with a healthcare provider who understands your health status, medications, and melatonin sensitivity.

Is natural melatonin from food better than supplements?

Natural melatonin from food (tart cherry juice, kiwifruit, tomatoes, nuts, seeds) provides 0.1–1 mg depending on source. This is a much lower dose than most supplements. For people with age-related melatonin decline or shift workers with severely disrupted circadian rhythms, dietary sources alone may not restore optimal melatonin physiology. However, dietary melatonin avoids the absorption and dosing questions surrounding supplements and comes with other phytonutrients. An optimal approach for many people combines dietary melatonin from whole foods with circadian rhythm optimization, adding supplements only if other interventions prove insufficient.

Conclusion

Melatonin is linked to disease in seemingly contradictory ways: low melatonin production increases disease risk, while long-term melatonin supplementation increases disease risk in certain populations. This paradox resolves when you understand that physiology and pharmacology are different. Your body tightly regulates melatonin secretion—rising and falling with circadian precision. Supplementation bypasses these controls, creating different physiological conditions than health or disease.

The practical takeaway: melatonin is most useful for specific short-term applications (jet lag, shift work adaptation, acute insomnia) and potentially beneficial for early neurodegenerative disease prevention. Long-term daily supplementation, particularly at high doses or in populations with baseline cardiovascular disease, requires medical supervision. Optimized delivery systems that achieve therapeutic effects at lower doses reduce long-term risk from chronic supraphysiological melatonin exposure.

Start with evidence-based sleep hygiene, circadian rhythm optimization, and light management—the foundation of any sleep improvement program. Add melatonin supplementation only when other approaches prove insufficient, with medical guidance on appropriate dosing and duration for your specific situation.

Research References

1. Nnadi E, et al. Effect of Long-term Melatonin Supplementation on Incidence of Heart Failure in Patients with Insomnia. Circulation. 2025;152(Suppl 3):4371606. (Large prospective cohort, 130,828 adults, 5-year follow-up)
2. Iyer S, et al. Exogenous Melatonin and Sleep Quality: A Scoping Review of Systematic Reviews. Journal of Clinical Pharmacology. 2026;60(2). (Comprehensive scoping review of 57 systematic reviews, 227 meta-analyses)
3. Moawad H. Fad or Fixture: Melatonin for Sleep and Cognition. Medscape Medical Commentary. 2026. (Clinical expert review addressing recent evidence contradictions)
4. Talbot N, et al. Neuroprotective Potential of Melatonin: Evaluating Therapeutic Efficacy in Alzheimer's and Parkinson's Diseases. Cureus. 2023;15(12):e50948. (Comprehensive review, 100+ citations)
5. Unveiling Mysteries of Aging: The Potential of Melatonin in Preventing Neurodegenerative Diseases in Older Adults. PMC Database. 2024. (Mechanistic review focusing on aging populations)
6. Melatonin in Alzheimer's Disease: Literature Review and Therapeutic Trials. PMC. 2024. (Clinical trial synthesis, dosing recommendations)
7. Melatonin: A Potential Nighttime Guardian Against Alzheimer's. Molecular Psychiatry. 2024;28. (Mechanistic review, tau and amyloid pathways)
8. The Antiapoptotic Activity of Melatonin in Neurodegenerative Diseases. PMC. 2008;175:3263-3280. (Foundational mechanisms review)
9. Melatonin in Alzheimer's Disease and Other Neurodegenerative Disorders. PMC. 2001. (Historical landmark review, mitochondrial dysfunction)
10. Srinivasan V, et al. Melatonin and the Metabolic Syndrome: A Tool for Effective Therapy in Obesity-Associated Abnormalities? Neuroendocrinology Letters. 2009;30(2). (Metabolic mechanism review)
11. Mostafa MT. Effects of Melatonin on Cardiovascular Risk Factors and Metabolic Syndrome: A Comprehensive Review. Vascular Health and Risk Management. 2020;16. (210-article systematic review)
12. Melatonin and Metabolic Disorders: Unraveling the Interplay With Glucose and Lipid Metabolism, Adipose Tissue, and Inflammation. Sleep Medicine Research. 2024;15(1). (Mechanistic focus on insulin signaling)
13. Ruan Y, et al. Use of Melatonin Supplements and Risk of Type 2 Diabetes and Cardiovascular Diseases in the USA: Insights from Three Prospective Cohort Studies. The Lancet Diabetes & Endocrinology. 2024;12(5). (Nurses' Health Study, 23-year follow-up, 159,000+ participants)
14. Circadian Dysfunction and Cardio-Metabolic Disorders in Humans. Frontiers in Endocrinology. 2024;15:1328139. (Circadian physiology focus)
15. Melatonin-Insulin Interactions in Patients with Metabolic Syndrome. Nutrition & Metabolism. 2008;5:27. (Endocrine mechanism review)
16. Melatonin and the Metabolic Syndrome. Springer. 2012;7. (Obesity and insulin resistance focus)
17. Yi-Wen C, et al. Effects of Melatonin on Glucose Homeostasis, Antioxidant Ability, and Adipokine Secretion in ICR Mice with NA/STZ-Induced Hyperglycemia. PMC. 2015;5:e008887. (Mechanistic animal model study)
18. Melatonin, Sleep Disturbance and Cancer Risk. ScienceDirect. 2008;14(6):545-562. (Cancer risk and circadian disruption)
19. Rethinking Melatonin Dosing: Safety and Efficacy at Higher-than-Usual Levels in Aged Patients with Sleep Disturbances and Comorbidities. PMC. 2024. (High-dose clinical experience, Italian cohort)
20. Continued Use of Melatonin for Insomnia Is Associated with an Increased Risk of Heart Failure. Spanish Society of Sleep Medicine. 2025;November. (Commentary on Nnadi study by sleep medicine experts)
21. Long-Term Use of Sleep Supplement Melatonin Linked to Potential Heart Risks. Baptist Health Miami Cardiac Institute. 2025;November. (Clinical expert interpretation)
22. Exogenous Melatonin and Sleep Quality: A Scoping Review of Systematic Reviews. PMC. 2026;12(1):1-15. (Most recent comprehensive evidence summary)
23. Sleep Foundation. Melatonin: Usage, Side Effects, and Safety. 2025. (Consumer-facing authoritative source, 2-3 citations)
24. Sleep Foundation. Sleep Hygiene: Your Guide to Better Sleep. 2025. (Behavioral sleep optimization, complementary to melatonin)
25. Evaluating the Disease Modifying Potential of a Sleep Intervention on Alzheimer's Disease Biomarkers. NIH Clinical Trials. 2024. (Ongoing melatonin supplementation trial in cognitive impairment)
26. Xu JS, et al. Melatonin and Dementia: A Systematic Review and Meta-Analysis. International Psychogeriatrics. 2015;27(12). (Foundational meta-analysis, sleep and cognition in dementia)

About the Author

David Kimbell is a research scientist and health content specialist with expertise in sleep physiology, circadian biology, and evidence-based supplementation. With a background in biochemistry and a decade of health science writing, he synthesizes clinical research into practical guidance for health-conscious readers and healthcare practitioners. David works with clinical researchers, academic institutions, and healthcare companies to translate complex scientific evidence into actionable health information. When not writing, he's optimizing his own sleep protocols and exploring how circadian biology intersects with metabolic health. David holds credentials in health content creation and maintains ongoing professional education in nutrition science and clinical research methodology.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Melatonin can interact with medical conditions and medications in complex ways. The disease associations discussed—particularly the cardiovascular risk with long-term use—warrant medical evaluation. Always consult with a qualified healthcare provider before starting melatonin supplementation, especially if you have cardiovascular disease, neurological conditions, metabolic disorders, take medications, are pregnant or nursing, or are considering melatonin for a child. Individual responses to melatonin vary significantly. This article does not constitute a recommendation for or against melatonin use—only your healthcare provider can make that determination based on your specific health status, medications, and risk factors.

FDA/Health Canada Disclaimer: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.